The efficacy of ranibizumab treatment in patients with macular choroidal neovascularization
CHEN Li-fei
LI Min
WU Xue-jin
Abstract：Objective To evaluate the efficacy and safety of intravitreal injection of ranibizumab for macular choroidal neovascularization( CNV) .Methods Twenty-six eyes of 26 patients diagnosed with macular choroidal neo-vascularization caused by age-related macular degeneration, high myopia macular degeneration and central exudative retinopathy were included in this study.Intravitreal injections of ranibizumab(0.5 mg/0.5 ml) were performed on all eyes.All patients were followed-up for 3 months, and the best-corrected visual acuity(BCVA), the central macular thickness( CMT) and complications were recorded.Results During the follow-up period, the mean of BCVA im-proved from (17.65 ±13.96) letters to (34.23 ±16.36) letters after a follow-up of 3 months(P<0.05);the mean of CMT decreased from (310.84 ±113.13)μm to (198.76 ±46.90)μm after a follow-up of 3 months(P<0.05). Retinal detachment, endophthalmitis, lens injury and systemic adverse reactions were not found.Conclusion Intrav-itreal injection of ranibizumab is an effective and safe treatment for macular CNV.
Keywords：RanibizumabChoroidal neovascularizationIntravitreal injection
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 125-127 )